

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 1/17


Application Number  
09/545,316

FIG. 1




FIG. 2

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 2/17

Application Number  
09/545,316




FIG. 3

FIG. 4

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 3/17

Application Number  
09/545,316

The screenshot shows the JournalSoft Manuscript Management System interface. At the top, there's a navigation bar with links for Home, Help, Personal Tools, and Logout. Below the navigation bar is a menu bar with File, Edit, View, Favorites, Tools, Help, and a magnifying glass icon. A sidebar on the left contains links for My JournalSoft, View Manuscripts, Personal Data, Preferences, MetaData, Help, and Logout. The main content area has several sections:

- MANUSCRIPTS TO REVIEW**: A box containing the URL <http://141.214.77.50/jsoft/index5.php?37&usestype=reviewer&home=0>.
- YOUR COMPLETED REVIEWS**: A box showing a review for manuscript ID 3728, titled "Diseases and Tumors Susceptible to Cancer Risk and on the Human Genome". It includes a note: "Your review is 243 day(s) overdue. Please submit it promptly." and "Other review reached on 28-Jul-1998. You will be able to read this review after you have submitted your own."
- JournalSoft**: A logo with the text "JournalSoft" and "You are logged in with EDITOR IN CHIEF".
- Footer**: A copyright notice "© 1998 Elsevier Science Ltd. All rights reserved."

FIG. 4A

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 4/17

Application Number  
**09/545,316**

**JournalSoft Manuscript Management System - Microsoft Internet Explorer**

File Edit View Favorites Tools Help

Back Stop Reload Home Search Favorites History Mail Print Discuss

Address: Back to JournalSoft Manuscript Management System

**MANUSCRIPTS TO REVIEW      YOUR COMPLETED REVIEWS**

You have completed 5 reviews. Thank you.  
To view the reviews please click on the thumb icons.

Legend:  
E = Suggest acceptance.  
M = Suggest major or minor revisions.  
D = Suggest rejection.

**99-121**  
Author: Teng-Chang Lin  
Title: Influence of P21 Inhibition on Human Neutrophils on P21-Dependent Differentiation Responses  
Status: Your review received 4 days ago on 22-Jan-1999.  
Other reviews received on 21-Jan-1999.  
Declined publication on 21-Jan-1999.

**99-127**  
Author: Aron, et al.  
Title: The Apoptotic Cell Death and Soul of the Cell Death Machine  
Status: Your review received on 19-Jan-1999.  
Other reviews received on 19-Jan-1999.  
Accepted pending major revision on 19-Jan-1999.  
Revised due by 19-Feb-1999.

**99-136**  
Author: Li, et al.  
Title: The effect of cyclosporine in combination with doxorubicin on the sensitivity of normal and carcinoma cells to methotrexate in vitro  
Status: Your review received on 24-Feb-1999.  
Other reviews received on 24-Feb-1999.  
Declined publication on 24-Feb-1999.

**99-176**  
Author: Liu, et al.  
Title: The anticancer drug Taxol blocks cdk5/p35 kinase activity in human malignant melanoma cells to promote apoptosis. Cdk5/p35 kinase with interactions in the expression of the cyclin-dependent kinase inhibitors  
Status: Your review received on 01-Apr-1999.  
Other reviews received on 01-Apr-1999.  
Accepted publication on 10-Jun-1999.

**99-209**  
Author: David, et al.  
Title: Gene expression profile of malignant glioma cells  
Status: Your review received on 10-Jun-1999.  
Other reviews received on 10-Jun-1999.  
Declined publication on 11-Jun-1999.

JournalSoft  
You are logged in with EDITOR privileges

Resources: New | Test | Created

Internet Explorer




FIG. 4B

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 5/17

Application Number  
09/545,316

**Journalsalt Manuscript Management System - Microsoft Internet Explorer**

File Edit View Favorites Book Help

Back Stop Refresh Home Search Favorites History Help

Address Links

**Martin Block** Paper Sent: 11-Dec-1998 Review Due: 25-Dec-1998 Review Received: 22-Dec-1998

**RECOMMENDATION**  Accept

**THIS REVIEW IS MARKED AS A DRAFT.**  
**IT HAS NOT YET BEEN MADE AVAILABLE TO THE EDITORS AND AUTHORS.**

RATINGS	Top 5%	Top 10%	Top 25%	Top 50%	Bottom 50%	No Comment
<b>Scientific Quality</b>	<input type="radio"/>					
<b>Significance</b>	<input type="radio"/>					
<b>Originality</b>	<input type="radio"/>					
<b>Clarity</b>	<input type="radio"/>					

**COMMENTS TO THE AUTHORS**

This study is a very nice experiment to validate the authors' hypothesis that radiosensitization FdUrd exposure depends on progression of cells through the S phase during drug exposure. Unfortunately the difference between the radiosensitization of the two E7-expressing clones and the parental cells is not as convincing as one would have liked. There also seem to be discrepancies between some of the reported data in the text and the tables (see below).

&lt;U&gt;Specific Comments&lt;/U&gt;

1. Table I: The TS activity in the E7.9 clone during FdUrd exposure is much larger than that of the controls and is certainly not greater

**THIS REVIEW IS CURRENTLY MARKED AS A DRAFT**

Done  Pending

FIG. 4C

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 6/17


Application Number  
09/545,316

FIG. 5

FIG. 6

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 7/17

Application Number  
09/545,316

**Journalsolt Manuscript Management System - Microsoft Internet Explorer**

File Edit View Favorites Help

Back Forward Stop Refresh Home Search Favorites History Help

Address Links

RATINGS	Top 5%	Top 10%	Top 25%	Top 50%	Bottom 50%	No Comment
Scientific Quality	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Significance	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Originality	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Clarity	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**COMMENTS TO THE AUTHORS**

This study is a very nice experiment to validate the authors' hypothesis that radiosensitization FdUrd exposure depends on progression of cells through the S phase during drug exposure. Unfortunately the difference between the radiosensitization of the two E7-expressing clones and the parental cells is not as convincing as one would have liked. There also seem to be discrepancies between some of the reported data in the text and the tables (see below).

Specific Comments

1. Table I: The TS activity in the E7.9 clone during FdUrd exposure is much larger than that of the controls and is certainly not greater than 95% inhibited as indicated in the text (p. 8, par. 1).
2. Figure 1: Why are the data for only one experiment shown? It would seem to make more sense to show the data for all experiments with mean and standard errors for each point for the pooled data.

We are sorry that the reviewer seemed confused by this figure. In fact, it was a plot of mean values. We have added error bars and refined the caption to make this more clear.

3. P. 5, par. 3: The use of mean inactivation dose is perhaps the best way to analyze data fitted with the linear-quadratic model, but it is really an arcane method that will not be understood by 95% of the readers. If the authors have to use this method, they should indicate that the method heavily weights the initial part of the survival curve (for example, all data above 10% surviving fraction) and therefore, heavily weights the alpha component.

Done Print

**FIG. 5A**

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 8/17

Application Number  
09/545,316




FIG. 7

FIG. 8

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 9/17


Application Number  
**09/545,316**

FIG. 9

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 10/17

Application Number  
09/545,316

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Find ECR

Address: [Links](#)

**Fill out the form below completely to register.**

**1. Your Login Information**

**Username**  
Please enter the username you would like to use to login to JournalSoft:

**Password**  
Please enter a password that you can easily remember. Passwords are case-sensitive and should contain between 3 and 10 characters. The most secure passwords contain letters and numbers.  
 Please enter your favorite password:  
 Confirm password:  
 Please enter your main EMAIL address:

You may enter a clue to your password to help you remember it in the future:

Journalsoft | [Help](#) | [Feedback](#) | [Logout](#)

FIG. 10

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 11/17

Application Number  
09/545,316

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Help Print Help

Address: [Links](#)

**Fill out the form below completely to register.**

**2. Enter your contact information below.**

Name:		
Address:		
City, State and Zip Code:		
Country:	- Select Continent - <input type="button" value="&lt;--&gt;"/>	
Phone:	(Not Required)	
Fax:	(Not Required)	
Text Pager Email or Web Paging Address	(Not Required)	
If you have a Web Site, you can include your URL in the AD	Enter exactly as shown here: <b>www.yourdomain.com</b> <b>DO NOT BEGIN YOUR ADDRESS WITH "http://".</b>	

© 2006 Journalsoft

FIG. 11

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 12/17

Application Number  
09/545,316

**Journalsoft Manuscript Management System - Microsoft Internet Explorer**

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Find Stop

Address: Links

**Fill out the form below completely to register.**

**3. Please tell us about your research interests**

In the space below please write a **SHORT NARRATIVE** about your research interests **OR** enter a list of **KEYWORDS** describing areas of research in which you are interested.

This information will be used to help us assign appropriate reviewers for your submissions and to find papers that you may be interested in reviewing for **Neoplasia** should you agree to serve as a reviewer.

**Comments:**

Close





FIG. 12

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 13/17

Application Number  
09/545,316

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 14/17

Application Number  
09/545,316

**Journalsoft Manuscript Management System - Microsoft Internet Explorer**

File Edit View Favorites Help

Back Stop Refresh Home Search Favorites Window Help

Address: [http://www.journalsoft.com/journalsoft/submit.asp](#)

**Fill out the form below completely to register.**

**5. JournalSoft Preferences.**

Please enter your preferences so we can customize your JournalSoft experience.

Please remember that you can change these options at any time in the future.

Would you like to review papers for Neoplasia?	<input type="radio"/> YES <input type="radio"/> NO
If so, please enter any dates when you will not be available to review manuscripts (MMDDYY-MMDDYY). Enter each separate period on a new line.	<input type="text"/>
How would you like us to request reviews from you?	<input type="radio"/> On your JournalSoft webpage only. <input type="radio"/> By E-Mail. <input type="radio"/> By Phone. <input type="radio"/> By Fax. <input type="radio"/> By Text Pager.
How would you like us to notify you when a manuscript which you have submitted passes through a peer-review milestone such as a review being received or an editorial decision being made?	<input type="radio"/> On your JournalSoft webpage only. <input type="radio"/> By E-Mail. <input type="radio"/> By Phone. <input type="radio"/> By Fax. <input type="radio"/> By Text Pager.

**Continue**

Done

FIG. 14

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 15/17

Application Number  
09/545,316

JournalSoft Manuscript Management System - Microsoft Internet Explorer

Address [5] <http://141.214.77.150/jsoft/index5.php?37name=persusestype=editor>

# Neoplasia Manuscript Tracking Center

Powered by JournalSoft 2.0.1

Welcome to the Neoplasia manuscript tracking website.  
It is Tuesday March 28, 2000 at the main Neoplasia Editorial Offices.

**REMINDERS**

You have agreed to review 1 paper for Neoplasia.  
You have 3 papers currently under consideration for publication in Neoplasia.

**My JournalSoft**

**View Manuscripts**

**Personal Data**

**Preferences**

**MetaData**

**Help**

**Logout**

**JournalSoft**

You are logged in with  
EDITOR privileges.

FIG. 15

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 16/17

Application Number  
**09/545,316**

**JournalsSoft Manuscript Management System - Microsoft Internet Explorer**

**File Edit View Favorites Tools Help**

**Back Forward Stop Refresh Home Mail**

**Address: https://www.journalssoft.net/**

**My JournalsSoft**

**View ▾**

**Manuscripts**

**Personal Data**

**Preferences**

**MetaData**

**Help ▾**

**Logout**

**CONTRIBUTING AUTHOR**

You are the Corresponding Author for the following 2 manuscripts  
To view or respond to reviews please click on the track bars.

**EJ** = Suggested acceptance  
**U** = Suggested major or minor revisions  
**EP** = Suggest rejection

Review 1 received 59 days(s) late on 25-Jan-2000.
Review 2 received 49 days(s) late on 17-Feb-2000
Review 3 received 286 day(s) late on 05-Mar-1999

**SG-110**

Stephen L. Ross, Ph.D.,  
Collaborative Assessment of Prostaglandin  
and Thromboxane Receptor Agonists in Intraoperative  
Enzymatic Conversion & Selection for  
Residues and/or Arachidic  
Research Center

**SG-110**

Stephen L. Ross, Ph.D.,  
Collaborative Assessment of Prostaglandin  
and Thromboxane Receptor Agonists in Intraoperative  
Enzymatic Conversion & Selection for  
Residues and/or Arachidic  
Research Center

**Journal of**

You are logged in with  
**Editor Privileges**

**Editorial Metrics Enabled**

FIG. 16

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 17/17

Application Number  
09/545,316

The screenshot shows a web-based manuscript management system. At the top, there's a navigation bar with links for File, Edit, View, Personal Tools, Help, Back to Manuscript Management System, Address, and Log Out. Below this is a sidebar with links for My JournalSoft (selected), View Manuscripts, Personal Data, Preferences, MetaData, Help (with a dropdown menu), Logout, and a logo for "Journal of".

The main content area has two sections:

- CONTRIBUTING AUTHOR:** Shows a list of authors: Theodore S. Ross, Michael C. Epperson, and others. It includes a link to "View or respond to reviews" and a note about a 17-day overdue review.
- REVIEW HISTORY:** A table showing the status of two reviews:
 

Review	Status	Comments
Review 1	Received 4/28/98 (S) late on 22-Dec-1998	Major or minor revisions suggested
Review 2	Received 4/28/98 (S) late on 21-Dec-1998	Major or minor revisions suggested

At the bottom right, there's a note: "You are logged in with EDITOR privileges".

FIG. 17